| Ytd | -89.61% | |
| 1y | -98.75% |
| Open | 1.41 | Prev Close | 1.38 | Low | 1.38 | High | 1.42 | Mkt Cap | 1.21M |
| Vol | 22.95K | Avg Vol | 3.90M | EPS | -8.04 | P/E | -0.17 | Forward P/E | N/A |
| Beta | 3.49 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.73 | 200-d Avg | 11.24 | 1yr Est | 0.00 |
PPCB News
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceuti
MELBOURNE, Australia, July 21, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pro
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's
Importantly, both parties intend to approach the collaboration in a spirit of openness, scientific r
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceuti
Friedman Industries Inc (NASDAQ: FRD) rose in pre-market trading after posting strong Q4 earnings. O
US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Indus
US stocks up, Dow gains 250 pts. Dow up 0.58% while NASDAQ up 0.67%. Materials shares jump 1.5%, com
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceuti
The Company plans to file a Clinical Trial Application (CTA) in Australia for a Phase 1b, First-In-H
Based in Europe, the CDMO provides end-to-end services for preclinical and clinical projects, with e
Propanc Biopharma (NASDAQ:PPCB) reported quarterly losses of $(0.28) per share. This is a 97.76 perc
